Here is the latest stock price and chart of BIOCON . For more details, see the BIOCON company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
Watch Now: A Massive 15x Opportunity in Electric Vehicles
Live BSE Quotes | May 23, 2022 (Close) | ||
---|---|---|---|
Price (Rs)337.80 | Open (Rs) 340.20 | High (Rs) 343.80 | Low (Rs) 336.65 |
% Change-0.54 | Volume 37,093 | Value (Rs) 12,597,249 | 52-Week H/L 420.25 / 314.90 |
Live NSE Quotes | May 23, 2022 (Close) | ||
---|---|---|---|
Price (Rs)338.05 | Open (Rs) 342.05 | High (Rs) 343.80 | Low (Rs) 336.35 |
% Change-0.57 | Volume 1,242,086 | Value (Rs) 422,094,907 | 52-Week H/L 420.25 / 314.80 |
Change | |||||
---|---|---|---|---|---|
1 Day -0.54% | 1 Month -11.27% | 3 Months -14.45% | 1 Year -11.87% | 5 Years (CAGR)* -18.62% | 10 Years (CAGR)* 4.62% |
* Compound Annual Growth Rate
Valuation | ||||
---|---|---|---|---|
EPS (Rs)* 8.15 | P/E Ratio (x) 41.45 | Market Cap (Rs m) 405,562.68 | P/BV (x) 5.43 | Dividend Yield (%) 0.00 |
*Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
S&P BSE SENSEX ![]() |
||||||
PERIOD |
BIOCON last traded price was down 0.5% to Rs 337.8 on the BSE. On the NSE, BIOCON last traded price was down 0.6% to Rs 338.1. The total volume of shares traded was 1.3 m.
Overall, the broader S&P BSE HEALTHCARE Index was down by 1.0%. And the benchmark S&P BSE SENSEX was at 54,288.6 (down 0.1%).
Over the last 30 days, the BIOCON share price is down 4.2%. And over the last one year, BIOCON share price is down 11.9%.
The current market capitalisation of BIOCON stands at Rs 405,562.68 m. For more information, check out the list of top 100 companies in India in terms of market cap.
As of March 2022, company promoters held 60.64% stake in BIOCON , with no shares having been pledged. To know more, check out the latest shareholding pattern of BIOCON .
What else is happening in the markets today? Dig in...
After opening on a positive note, Indian share markets failed to keep up early gains and ended the day marginally lower.
For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.
During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.
The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?
For the Nifty pharma index, it seems as if bulls are losing ground as they witness multiple bearish candlestick patterns.
The strong momentum in India's IPO market is poised to continue with the market regulator approving the IPOs of three firms including PharmEasy.
More Views on NewsWe are just two months into 2022 and several penny stocks that we track have already surged 5x.
Debt free penny stocks are vital when it's a question of portfolio diversification in a volatile market. They can potentially offer good profitability in the long run.
A step-by-step method to pick the best penny stocks for the long term.
These penny stocks can become future multibaggers. Watch out for them.
Rising electricity consumption provides a lot of scope for growth. Which company has a better chance at capturing it?
More